Related Experiment Video
Updated: Dec 28, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Comprehensive pharmacogenomic characterization of gastric cancer
Jason K Sa1, Jung Yong Hong2, In-Kyoung Lee2
1Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
Background:
Gastric cancer is among the most lethal human malignancies. Previous studies have identified molecular aberrations that constitute dynamic biological networks and genomic complexities of gastric tumors. However, the clinical translation of molecular-guided targeted therapy is hampered by challenges. Notably, solid tumors often harbor multiple genetic alterations, complicating the development of effective treatments.
Methods:
To address such challenges, we established a comprehensive dataset of molecularly annotated patient derivatives coupled with pharmacological profiles for 60 targeted agents to explore dynamic pharmacogenomic interactions in gastric cancers.
Results:
We identified lineage-specific drug sensitivities based on histopathological and molecular subclassification, including substantial sensitivities toward VEGFR and EGFR inhibition therapies in diffuse- and signet ring-type gastric tumors, respectively. We identified potential therapeutic opportunities for WNT pathway inhibitors in ALK-mutant tumors, a significant association between PIK3CA-E542K mutation and AZD5363 response, and transcriptome expression of RNF11 as a potential predictor of response to gefitinib.
Conclusions:
Collectively, our results demonstrate the feasibility of drug screening combined with tumor molecular characterization to facilitate personalized therapeutic regimens for gastric tumors.
Insights
This study explores targeted therapies for gastric cancer by analyzing molecular data and drug responses. Findings reveal specific drug sensitivities and potential treatment predictors, paving the way for personalized gastric cancer therapies.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Gastric cancer is a highly lethal malignancy with complex genomic alterations.
- Clinical translation of molecularly-guided therapies is challenging due to tumor heterogeneity.
- Multiple genetic alterations in solid tumors complicate effective treatment development.
Purpose of the Study:
- To establish a comprehensive dataset of molecularly annotated gastric cancer patient derivatives.
- To profile responses to 60 targeted agents to explore pharmacogenomic interactions.
- To identify personalized therapeutic strategies for gastric tumors.
Main Methods:
- Created a dataset of patient-derived molecular profiles.
- Performed drug screening with 60 targeted agents.
- Analyzed pharmacogenomic interactions in gastric cancer.
Main Results:
- Identified lineage-specific drug sensitivities, including VEGFR and EGFR inhibitors for diffuse and signet ring types.
- Found potential for WNT pathway inhibitors in ALK-mutant tumors.
- Linked PIK3CA-E542K mutation to AZD5363 response and RNF11 expression to gefitinib response.
Conclusions:
- Demonstrated feasibility of combining drug screening with molecular characterization.
- Facilitated personalized therapeutic regimens for gastric tumors.
- Highlighted potential for precision medicine in gastric cancer treatment.
